source
- Genmab’s Rina-S ADC shows 9.5-month median PFS, touted as superior to AbbVie’s ElahereGenmab reported median progression‑free survival of 9.5 months for its FRα‑directed antibody‑drug conjugate Rina‑S in part C of the phase 1/2 Rainfol‑01 trial, which enrolled 109 patients with plat…
- Leerink analyst downgrades Bristol Myers over pipeline concernsA Leerink analyst signaled new bearishness on Bristol Myers Squibb, downgrading the company's stock rating. Analyst David Risinger moved the rating from outperform to a lower stance, saying he is…